ENHERTU Plus Pertuzumab Gets US Priority Review for HER2+ Breast Cancer
September 24, 2025
Based on DESTINY-Breast09 phase 3 trial results, which showed ENHERTU plus pertuzumab reduced the risk of disease progression or death by 44% versus THP with